한글목차

혈장 증량제 세계 시장 규모는 2024년 73억 2,000만 달러, 2030년에는 150억 3,000만 달러로 성장할 것으로 예상되며, 12.71%의 연평균 복합 성장률(CAGR)을 나타낼 것으로 예상됩니다.

이 시장은 외상, 수술, 화상, 쇼크와 같은 심각한 상태에서의 체적 보충에 대한 헬스케어 수요 증가를 배경으로 크게 확대될 것으로 예상됩니다. 혈장 증량제는 혈액량 회복에 도움이 되는 중요한 정맥주사제이며, 심각한 탈수 및 혈액 손실 치료에 필수적입니다. 또한 심부전, 간질환, 신장질환과 같은 만성질환의 유병률 증가는 이들 제품에 대한 수요를 더욱 가속화시키고 있습니다. 중증 환자의 체액 균형 관리와 심혈관 건강 유지에 중요한 역할을 하기 때문입니다. 수술 및 집중 치료의 빈도가 증가하고 있는 것도 시장 성장에 박차를 가하고 있습니다.

혈장 확장제 시장의 급속한 성장에는 몇 가지 요인이 기여하고 있습니다. 하이드록시에틸전분(HES) 및 기타 합성 콜로이드와 같은 합성 혈장 확장제의 채택이 증가하고 있으며, 이는 인간 알부민에 비해 효과와 비용 효율성이 높기 때문에 성장을 주도하고 있습니다. 혈장 확장제 제조 및 제형화 기술의 발전으로 안전성과 유효성이 향상되고, 의료진에게 접근성과 신뢰성이 높아지면서 혈장 확장제의 사용이 확대되고 있습니다. 첨단 의료 기술로의 전환과 전 세계적으로 중증 환자 관리에 대한 관심이 높아지면서 응급 및 중환자 치료에서 중요한 역할을 하는 혈장 확장기에 대한 투자도 증가하고 있습니다. 보다 안전하고 효과적인 치료 옵션에 대한 수요는 이 분야의 기술 혁신을 촉진하고 있으며, 새로운 제형은 부작용과 안전성 프로파일에 대한 문제를 해결하고 있습니다.

그러나 이 시장은 성장에 영향을 미칠 수 있는 몇 가지 과제에 직면해 있습니다. 가장 큰 우려는 특정 합성 혈장 증량제, 특히 하이드록시에틸전분(HES)의 잠재적인 부작용으로, 일부 사례에서 신장 손상으로 이어질 수 있다는 점입니다. 신제품 승인 및 복잡한 임상시험과 관련된 규제상의 문제로 인해 새로운 치료법의 도입이 지연될 수 있습니다. 혈장 유래 제제는 고가이기 때문에 자원이 부족한 환경에서는 접근성이 제한적이며, 인간 알부민과 같은 인간 유래 제제에 의존할 경우 공급 부족, 윤리적 고려 사항, 병원체 전파 위험 등의 문제가 발생할 수 있습니다. 이러한 문제를 해결하기 위해 시장은 보다 안전하고 효과적인 대체품 개발에 집중하고, 전 세계적으로 증가하는 혈장 확장제 치료에 대한 수요에 대응하기 위해 접근성을 개선하기 위해 노력해야 합니다.

주요 시장 성장 촉진요인

기술 발전

주요 시장 이슈

비용 절감

주요 시장 동향

수혈보다 혈장 확장제로의 전환:

목차

제1장 개요

제2장 조사 방법

제3장 주요 요약

제4장 고객의 소리

제5장 세계의 혈장 증량제 시장 전망

• 시장 규모와 예측
  • 금액별
• 시장 점유율과 예측
  • 제품 유형별(Dextran, Hydroxyethyl Starch, Human Albumin, PEGylated Albumin, Polyvinylpyrrolidone (PVP), Gelatin)
  • 최종사용자별(온라인 약국, 소매 약국, 병원 약국)
  • 지역별
  • 기업별(2024년)
• 시장 맵

제6장 아시아태평양의 혈장 증량제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 아시아태평양 : 국가별 분석
  • 인도
  • 호주
  • 일본
  • 한국

제7장 유럽의 혈장 증량제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 유럽 : 국가별 분석
  • 독일
  • 스페인
  • 이탈리아
  • 영국

제8장 북미의 혈장 증량제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 북미 : 국가별 분석
  • 멕시코
  • 캐나다

제9장 남미의 혈장 증량제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 남미 : 국가별 분석
  • 아르헨티나
  • 콜롬비아

제10장 중동 및 아프리카의 혈장 증량제 시장 전망

• 시장 규모와 예측
• 시장 점유율과 예측
• 중동 및 아프리카 : 국가별 분석
  • 사우디아라비아
  • 아랍에미리트(UAE)

제11장 시장 역학

• 성장 촉진요인
• 과제

제12장 시장 동향과 발전

• 최근 동향
• 제품 출시
• 인수합병(M&A)

제13장 세계의 혈장 증량제 시장 : SWOT 분석

제14장 Porter의 Five Forces 분석

• 업계내 경쟁
• 신규 참여 가능성
• 공급업체의 힘
• 고객의 힘
• 대체품의 위협

제15장 PESTEL 분석

제16장 경쟁 구도

• Baxter International Inc
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

제17장 전략적 제안

제18장 리서치사에 대해 & 면책사항

영문목차

The Global Plasma Expander Market was valued at USD 7.32 billion in 2024 and is projected to grow to USD 15.03 billion by 2030, with a CAGR of 12.71%. This market is poised for significant expansion, driven by increasing healthcare demands for volume replacement in critical conditions such as trauma, surgery, burns, and shock. Plasma expanders, vital intravenous solutions, help to restore blood volume and are essential in treating severe dehydration and blood loss. Additionally, the rising prevalence of chronic conditions like heart failure, liver disease, and kidney disorders is further accelerating the demand for these products, as they play a crucial role in managing fluid balance and maintaining cardiovascular health for critically ill patients. The growing frequency of surgeries and intensive medical procedures is also fueling market growth.

Several factors are contributing to the rapid progress of the plasma expander market. The increasing adoption of synthetic plasma expanders, such as Hydroxyethyl Starch (HES) and other synthetic colloids, is driving growth due to their effectiveness and cost-efficiency compared to human albumin. Technological advancements in plasma expander manufacturing and formulation are improving their safety and efficacy, enhancing their accessibility and reliability for healthcare providers. The shift toward advanced medical technologies and a heightened focus on critical care management globally is also encouraging investments in plasma expanders, which are crucial in emergency and intensive care settings. Demand for safer and more effective treatment options is prompting innovation in this field, with new formulations addressing challenges related to side effects and safety profiles.

However, the market faces several challenges that may affect its growth. A key concern is the potential side effects of certain synthetic plasma expanders, particularly Hydroxyethyl Starch (HES), which has been linked to kidney damage in some instances. Regulatory challenges related to the approval of new products and complex clinical trials can delay the introduction of new therapies. The high cost of plasma-derived products limits accessibility in low-resource settings, and reliance on human-derived products, such as human albumin, raises concerns about supply shortages, ethical considerations, and the risk of pathogen transmission. To address these challenges, the market must focus on developing safer and more effective alternatives while improving accessibility to meet the growing demand for plasma expander treatments globally.

Key Market Drivers

Technological Advancements:

Researchers are actively working on developing new formulations of plasma expanders to improve volume-expanding properties while reducing side effects like coagulation disturbances and kidney injury. Advances are also being made in the creation of synthetic plasma expanders that do not rely on human or animal plasma, reducing the risk of infections and immunological reactions. The development of biodegradable plasma expanders, which break down naturally in the body over time, is also underway. Additionally, nanotechnology is being used to enhance the properties of plasma expanders by improving drug delivery, circulation time, and tissue targeting. Technological innovations have led to improved safety profiles, longer shelf life, and more accurate real-time monitoring of patient responses to plasma expanders. In India, for example, the Department of Science and Technology (DST) and the Central Institute of Petrochemicals Engineering & Technology (CIPET) have been pivotal in promoting research and development in this area, further contributing to the advancement of plasma expanders.

Key Market Challenges

Cost Containment:

Healthcare systems globally face budget constraints, leading to cost-containment measures that may impact the purchasing of plasma expanders. The plasma expander market is highly competitive, with multiple manufacturers offering a range of products, which may result in price pressure and reduced profit margins. Additionally, reimbursement policies from government and private insurers can impact the financial viability of plasma expander products, and economic downturns can shift preferences toward cost-effective alternatives. The high costs associated with research, development, and regulatory compliance also complicate the market dynamics, requiring manufacturers to balance affordability with profitability. Efficient supply chain management is essential for reducing costs related to production, distribution, and storage.

Key Market Trends

Shift Toward Plasma Expanders Over Blood Transfusions:

The preference for plasma expanders over blood transfusions is a major driver for market growth. While blood transfusions have traditionally been used to treat significant blood loss, they carry risks such as immunological reactions, infections, blood type mismatches, and allergic responses. Plasma expanders, by mimicking human plasma, offer a safer alternative as they do not carry the same risks of transfusion reactions and infections. They are easier to store, have a longer shelf life, and are more cost-effective than blood transfusions, which involve high costs for blood collection, screening, and storage. As healthcare systems focus on improving trauma care efficiency, plasma expanders are increasingly becoming the preferred method for volume restoration in critical patients, particularly in emergency settings and remote areas with limited access to blood banks.

Key Market Players

• Baxter International Inc.
• Fresenius SE & Co. KGaA
• CSL Limited
• Grifols, S.A.
• B. Braun Melsungen AG
• Hikma Pharmaceuticals PLC
• Octapharma AG
• Kedrion S.p.A.
• Shanghai RAAS Blood Products Co., Ltd.
• Terumo Corporation

Report Scope:

This report segments the Global Plasma Expander Market by product type, end-user, and region, highlighting industry trends and market dynamics.

Product Type Segmentation:

• Dextran
• Hydroxyethyl Starch
• Human Albumin
• PEGylated Albumin
• Polyvinylpyrrolidone (PVP)
• Gelatin

End-User Segmentation:

• Online Pharmacies
• Retail Pharmacies
• Hospital Pharmacies

Regional Segmentation:

• North America
• Asia-Pacific
• Europe
• South America
• Middle East & Africa

Competitive Landscape:

Detailed profiles of key market players are included in the report.

Available Customizations:

TechSci Research offers customization options for the Global Plasma Expander Market report, including additional market player analysis and other specific insights tailored to company needs.

Additional company analysis and profiling (up to five additional market players).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Plasma Expander Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Product Type (Dextran, Hydroxyethyl Starch, Human Albumin, PEGylated Albumin, Polyvinylpyrrolidone (PVP), Gelatin)
  • 5.2.2. By End User (Online Pharmacies, Retail Pharmacies, Hospital Pharmacies)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. Asia Pacific Plasma Expander Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Product Type
  • 6.2.2. By End User
  • 6.2.3. By Country
• 6.3. Asia Pacific: Country Analysis
  • 6.3.1. China Plasma Expander Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Product Type
      • 6.3.1.2.2. By End User
  • 6.3.2. India Plasma Expander Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Product Type
      • 6.3.2.2.2. By End User
  • 6.3.3. Australia Plasma Expander Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Product Type
      • 6.3.3.2.2. By End User
  • 6.3.4. Japan Plasma Expander Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Product Type
      • 6.3.4.2.2. By End User
  • 6.3.5. South Korea Plasma Expander Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Product Type
      • 6.3.5.2.2. By End User

7. Europe Plasma Expander Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Product Type
  • 7.2.2. By End User
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Plasma Expander Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Product Type
      • 7.3.1.2.2. By End User
  • 7.3.2. Germany Plasma Expander Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Product Type
      • 7.3.2.2.2. By End User
  • 7.3.3. Spain Plasma Expander Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Product Type
      • 7.3.3.2.2. By End User
  • 7.3.4. Italy Plasma Expander Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Product Type
      • 7.3.4.2.2. By End User
  • 7.3.5. United Kingdom Plasma Expander Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Product Type
      • 7.3.5.2.2. By End User

8. North America Plasma Expander Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Product Type
  • 8.2.2. By End User
  • 8.2.3. By Country
• 8.3. North America: Country Analysis
  • 8.3.1. United States Plasma Expander Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Product Type
      • 8.3.1.2.2. By End User
  • 8.3.2. Mexico Plasma Expander Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Product Type
      • 8.3.2.2.2. By End User
  • 8.3.3. Canada Plasma Expander Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Product Type
      • 8.3.3.2.2. By End User

9. South America Plasma Expander Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Product Type
  • 9.2.2. By End User
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Plasma Expander Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Product Type
      • 9.3.1.2.2. By End User
  • 9.3.2. Argentina Plasma Expander Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Product Type
      • 9.3.2.2.2. By End User
  • 9.3.3. Colombia Plasma Expander Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Product Type
      • 9.3.3.2.2. By End User

10. Middle East and Africa Plasma Expander Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Product Type
  • 10.2.2. By End User
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Plasma Expander Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Product Type
      • 10.3.1.2.2. By End User
  • 10.3.2. Saudi Arabia Plasma Expander Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Product Type
      • 10.3.2.2.2. By End User
  • 10.3.3. UAE Plasma Expander Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Product Type
      • 10.3.3.2.2. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global Plasma Expander Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

• 16.1. Baxter International Inc
  • 16.1.1. Business Overview
  • 16.1.2. Company Snapshot
  • 16.1.3. Products & Services
  • 16.1.4. Financials (In case of listed companies)
  • 16.1.5. Recent Developments
  • 16.1.6. SWOT Analysis
• 16.2. Fresenius SE & Co. KGaA
• 16.3. CSL Limited
• 16.4. Grifols, S.A.
• 16.5. B. Braun Melsungen AG
• 16.6. Hikma Pharmaceuticals PLC
• 16.7. Octapharma AG
• 16.8. Kedrion S.p.A.
• 16.9. Shanghai RAAS Blood Products Co., Ltd.
• 16.10.Terumo Corporation

17. Strategic Recommendations

18. About Us & Disclaimer